News & Updates

The use of sodium-glucose transporter 2 (SGLT2) inhibitors among patients with diabetes does not pose an increased risk of developing fractures as compared with dipeptidyl-peptidase 4 (DPP4) inhibitors, and this is true across estimated glomerular filtration rate (eGFR) and albuminuria categories, as shown in a study.

Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.

Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.

Use of educational pamphlets alone and individualized counselling (IC) both lead to improved uptake of influenza vaccination, reports a Singapore study, noting that IC is not superior to pamphlets alone in increasing uptake.

Initiation of a glucagon-like peptide-1 (GLP-1) agonist at standard glycaemic control doses may result in modest weight loss through 72 weeks in patients with overweight or obesity and type 2 diabetes, suggest the results of a real-world study.

In women with postpartum hypertension, treatment with combined hydrochlorothiazide (HCTZ)/lisinopril yields greater blood pressure (BP)-lowering benefit than nifedipine monotherapy, according to the results of a pilot study.